Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.42, read 2026-10-27
Ethical does not pass the values gate
Price35.84 USD
Fair value23.02
Ethical score10.0/100
RatingAVOID
Our investment reviews on this name
2026-10-26Read Markup34.26+4.6% to today ✓Markdown gives way to Markup after a 10% slide in 10 weeks
2026-08-15Read Markdown38.14-6.0% to today ✓Markup gives way to Markdown
2026-07-02Read Markup39.20-8.6% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
UDR, Inc. holds its Markup at $35.84. Consolidating, no directional conviction, held for 334 days.
As held on the ledger · 2026-10-23
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 334 days
Price at the screen
$35.84
Valuation
21.68 trailing · 61.18 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.71
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
56.61%
Below 33%
Interest-bearing debt is 56.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
8.36%
Below 33%
Cash held in interest-bearing accounts and securities is 8.4% of assets, under the one-third limit.
Pass
Receivables
1.43%
Below 49%
Money owed to the company is 1.4% of assets, under the 49% limit.
Pass
Revenue purity
1.12%
Below 5%
Only 1.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
UDR,'s business is in a permissible area, but its interest-bearing debt is about 57% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when UDR's ethical verdict changes
Today UDR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades above our $23.02 fair value estimate, moderate competitive moat.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. The price runs 35.8% above the base estimate.
Third-party analyst targets: 21 covering, consensus Buy. The average target sits +14% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
REIT rents look steady until debt mounts
Picture families paying rent on time every month while the landlord juggles heavy loans on every block. UDR trades at thirty nine dollars seventy six cents against our fair value of twenty three dollars fifty six cents, a forty one percent premium. Forward earnings sit at seventy one times on four percent revenue growth, and the ethical screen flags the debt ratio outright.
Moderate moat and twelve percent return on equity give little cover when profit margins rest at twenty eight percent. Residential REITs feel stable until rates stay high or vacancies creep up, turning yesterday's reliable cash flow into tomorrow's squeeze.
Analyst targets hover near forty one dollars yet the valuation gap and leverage breach keep us away. Analysis, not advice.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
UDR trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-30Markup$35.84+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (21 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$35.84+4.6%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (21 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$34.26+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (21 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$34.26+0.0%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (21 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup · changed$34.26+0.0%Entry 9
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (21 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$34.26+0.9%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (21 analysts) rates it buy, with a mean price target of $40.
2026-10-16Markdown$33.96+0.4%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (21 analysts) rates it buy, with a mean price target of $40.
2026-10-02Markdown$33.83-4.4%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (21 analysts) rates it buy, with a mean price target of $40.
2026-09-15Markdown$35.40-7.2%Entry 5
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 7.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (21 analysts) rates it buy, with a mean price target of $40.
2026-08-15Markdown · changed$38.14-2.7%Entry 4
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (21 analysts) rates it buy, with a mean price target of $40.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
